Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery

Trial Profile

Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Nepafenac (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top